AI Article Synopsis
- The study investigates the differences in marginal bone loss and implant failure between tilted and axial dental implants, highlighting the potential benefits and drawbacks of angulated implant positioning.
- An extensive literature search included 8 systematic reviews or meta-analyses, analyzing outcomes such as implant failure rates and bone loss measurements over different follow-up periods.
- Results showed no significant short-term differences in bone loss or implant failure between tilted and axial implants, but longer-term studies indicated slightly more bone loss associated with tilted implants over time, while overall failure rates were not significantly different.
Article Abstract
Purpose: To summarize and analyze all the evidence available concerning marginal bone loss (MBL) and implant failure between tilted and axial implants.
Materials And Methods: An electronic literature search was conducted without any language restrictions, and only systematic reviews with meta-analysis or meta-analysis studies were included. Relative risks (RRs) and the differences in mean (MD) were calculated with 95% confidence intervals (CIs) for the assessed outcomes (in mm) of implant failure and MBL.
Results: In total, eight studies were included. Based on the short-term results, a nonsignificant mean difference (MD = 0.00; 95% CI; -0.01-0.02; P value = .75) was recorded between tilted and axial implants supporting full-arch dentures. A significant mean difference was recorded at 3-year follow-up (MD = 0.08 95% CI= 0.05-0.11; P value < .00001) and at long-term follow-up (MD = 0.18; 95% CI = 0.15-0.20; P value < .00001). A nonsignificant difference was observed between tilted and axial implants regarding implant failure (RR = 1.02; 95% CI = 0.85-1.23;P value = .81).
Conclusions: Based on the high- and moderate-quality studies with low risk of bias included in this review, no significant difference in outcome regarding implant failure was observed between tilted and axial implants supporting full-arch or fixed partial dentures.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11607/jomi.10885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distal tibial fractures are common lower-limb injuries and are generally associated with a high risk of postoperative complications, especially in patients with multiple medical comorbidities. This study sought to ascertain the efficacy of retrograde intramedullary tibial nails (RTN) for treating extra-articular distal tibial fractures in high-risk patients. Between January 2019 and December 2021, 13 patients considered at high risk for postoperative complications underwent RTN fixation.
View Article and Find Full Text PDFProspective study of femoral neck system (FNS) vs. cannulated compression screw (CCS) fixation has not been appropriately reported. We prospectively investigate the efficacy of FNS vs.
View Article and Find Full Text PDFLarge-diameter heads (LDHs) in total hip arthroplasty (THA) enhance range of motion but require thinner liners. Monoblock acetabular components with ceramic liners could reduce liner fracture risks during modular acetabular component assembly. This study aims to confirm the safety and clinical performance of the monoblock Maxera Cup in THA.
View Article and Find Full Text PDFBreaking Barriers: Addressing Gender Disparities in Hip Resurfacing Surgery Access in the United States.
Arch Bone Jt Surg
January 2024
Orthopedic Research Center, Department of Orthopedic Surgery, Mashhad University of Medical sciences, Mashhad, Iran.
Second-generation large-diameter head hip resurfacing (HR) arthroplasty has gained popularity in terms of its potential for minimal wear and the preservation of proximal femoral bone stock. HR faces challenges, such as increased hip fracture rates and adverse reactions to metal detritus, despite the fact that over one million metal-on-metal (MoM) arthroplasties have been performed globally. FDA issued warnings in 2011 and 2016 regarding higher failure rates in women and categorized MoM implants as high-risk, influencing U.
View Article and Find Full Text PDFClinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial.
Front Cardiovasc Med
January 2025
Cardiology Service, Hospital Universitario de La Princesa, Madrid, Spain.
Introduction: Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.
Material And Methods: This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!